secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0001558370-23-008188
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

European Commission approves Protalix's PRX-102 for Fabry disease in EU
-----------------------------------------------------------------------

- EC granted marketing authorization to PRX-102 (pegunigalsidase alfa) for adult Fabry disease patients.
- Approval based on clinical program in >140 patients with up to 7.5 years of treatment.
- PRX-102 showed non-inferior efficacy to agalsidase beta in controlling kidney disease (eGFR decline).
- PRX-102 is not yet approved by FDA; U.S. review ongoing.
- Partner Chiesi Global Rare Diseases will commercialize in the EU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023008188/0001558370-23-008188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023008188/plx-20230505x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer